Apoptosis and lung cancer: A review
It is important to understand the molecular events that contribute to drug‐induced apoptosis, and how tumors evade apoptotic death. Defects in apoptosis are implicated in both tumorigenesis and drug resistance, and these defects are cause of chemotherapy failures. These studies should explain the re...
Gespeichert in:
Veröffentlicht in: | Journal of cellular biochemistry 2003-04, Vol.88 (5), p.885-898 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | It is important to understand the molecular events that contribute to drug‐induced apoptosis, and how tumors evade apoptotic death. Defects in apoptosis are implicated in both tumorigenesis and drug resistance, and these defects are cause of chemotherapy failures. These studies should explain the relationship between cancer genetics and treatment sensitivity, and should enable a more rational approach to anticancer drug design and therapy. Lung cancer is a major cause of cancer deaths throughout the world. Small cell lung carcinoma (SCLC) and non‐small cell lung carcinoma (NSCLC) represent the two major categories of lung cancer that differ in their sensitivity to undergo apoptosis. The role of apoptosis regulation in lung cancer with major focus on the differential sensitivities of the major subtypes is reviewed. J. Cell. Biochem. 88: 885–898, 2003. © 2003 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0730-2312 1097-4644 |
DOI: | 10.1002/jcb.10440 |